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GIVING PHARMACISTS PROVIDER RIGHTS
by: Tanya E. Karwaki*
ABSTRACT
Changes to our health care system, robotics and health care mergers among
them, are forcing pharmacists into expanded provider roles, yet federal policy-
makers are failing to act on these changes. State lawmakers are acting but not
swiftly enough. A federal response, including recognizing pharmacists as
health care providers and making them eligible for independent Medicare re-
imbursement, will be necessary to enable pharmacists to fill their role in our
health care system. Policymakers have an opportunity now to respond proac-
tively to a changing climate in health care by clarifying the boundaries on
pharmacists’ services, particularly those boundaries regarding direct patient
care and the appropriate reimbursement level. In doing so, policymakers may
also alleviate some of the scope of practice “turf wars” health care providers
engage in and incentivize better patient care and lower health care costs.
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I. INTRODUCTION
Many patients picking up a prescription from a drive-through phar-
macy on their commute home may consider the pharmacist as more of
a vendor than a health care provider, if they think of the pharmacist at
all. To these patients, pharmacists appear confined to a lick, stick,
count, and pour role.1 However, today’s pharmacists can also serve as
health care providers, giving the flu vaccine and other vaccines,2 pre-
scribing over-the-counter-nicotine-replacement patches and other
products,3 and rounding with hospital health care teams to provide
real-time advice about pharmaceutical therapies.4 This shift represents
a relatively recent change in pharmacists’ role in our health care sys-
tem from one of primarily selling drugs5 to providing more direct pa-
tient care. Indeed, pharmacists may improve patient care and decrease
health care costs, improvements our health care system needs with
over $528 billion in drug-related morbidity and mortality costs in one
year.6 At the same time pharmacy practice is changing, significant
health care system changes are also occurring, impacting pharmacists
and other health care providers. Combined, these changes illustrate a
growing gap between pharmacists’ provider role and the law’s failure
1. See generally Terence C. Green, Licking, Sticking, Counting, and Pouring — Is
That All Pharmacists Do? McKee v. American Home Products Corp., 24 CREIGHTON
L. REV. 1449, 1476 (1991).
2. Joan Vos MacDonald, State Laws and Vaccination Services, 163 DRUG
TOPICS 1, 18 (Dec. 2019), https://cdn.sanity.io/files/0vv8moc6/drugtopics/6cab
5bcc64db1ff15d3a17f19ef75a4092fb0b01.pdf [https://perma.cc/CJZ4-DNLD] (provid-
ing an overview of additional ways states regulate pharmacist-administered
vaccines).
3. See CAL. BUS. & PROF. CODE § 4052(a)(10) (West 2018).
4. See Gallegos v. Wood, No. CIV 13–1055, No. CIV 15–0184, 2016 WL 1426554,
at *1 (D.N.M. Mar. 31, 2016). Veterans Affairs and the Indian Health Service differ
from Medicare in recognizing pharmacists as providers. CMS Response Misses Point
of Provider Status, AM. PHARMACISTS ASS’N (Jan. 28, 2014), https://
www.pharmacist.com/CEOBlog/cms-response-misses-point-provider-status [https://
perma.cc/R6QH-63QF].
5. See David B. Brushwood, The Pharmacist’s Duty to Warn: Toward a Knowl-
edge-Based Model of Professional Responsibility, 40 DRAKE L. REV. 1, 3 (1991)
(describing one of a pharmacist’s many identities as that of a retail merchant).
6. Jonathan H. Watanabe, Terry McInnis & Jan D. Hirsch, Cost of Prescription
Drug-Related Morbidity and Mortality, 52 ANNALS PHARMACOTHERAPY 829, 829
(2018).
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to regulate them accordingly. Now is the time for federal legislators
and policymakers to proactively construct a federal solution giving
pharmacists provider rights within the context of broad changes to our
health care landscape.
Pharmacists seek provider status at the state and federal levels to
qualify for appropriate reimbursement for their services. Without pro-
vider status, pharmacists cannot be directly paid for many of the pa-
tient care services they are qualified to provide, as evidenced by
pharmacists’ inability to independently bill Medicare.
While federal pharmacist provider status may eventually be estab-
lished due to state lawmakers’ efforts to create a similar status at the
state level, this Article argues that changes in the health care system
are tipping towards dramatic, fast-paced change—one that will re-
quire regulation. Part II examines pharmacist provider status in the
context of the American health care system. Part III asserts that
changes in our health care landscape, including the increased use of
robots and automation in pharmacy practice and Amazon’s foray into
pharmacy, create a tipping point toward federal pharmacist provider
status. Part IV analyzes state statutes and federal efforts for how they
can inform future federal law. Finally, Part V highlights key issues and
possible solutions federal policymakers should consider in regulating
federal pharmacist provider status.
II. PHARMACIST PROVIDER STATUS AND THE AMERICAN HEALTH
CARE SYSTEM
Many aspects of our existing health care system may be improved if
pharmacists have provider status. Patients may gain increased access
to pharmacist-provided health care services, which are often closer to
home7 and available outside traditional primary care clinic hours.
Pharmacist provider status may also help reduce costs in the health
care system, with lower charges to the patients or their insurance com-
panies compared with physician-provided services. Moreover, im-
proved access to pharmaceutical care may save money on future
health care services8 by preventing or reducing further degree pro-
gression and development of comorbid conditions.9 Provider status
7. Approximately 93% of Americans live five miles or less from a pharmacy.
Nat’l Ass’n Chain Drug Stores, 2010–2011 Chain Pharmacy Industry Profile Illustrates
Pharmacy Value, DRUG TOPICS (Sept. 21, 2010), https://www.drugtopics.com/top-
news/nacds-2010-2011-chain-pharmacy-industry-profile-illustrates-pharmacy-value
[https://perma.cc/J3ND-84ZJ].
8. The U.S. Public Health Service Chief Pharmacist reported to the U.S. Surgeon
General that “for each dollar invested in the clinical pharmacy service . . . the overall
average benefit gained was $10.07 per $1 of allocated funds.” Scott Giberson, Sherri
Yoder & Michael P. Lee, Improving Patient and Health System Outcomes Through
Advanced Pharmacy Practice: A Report to the U.S. Surgeon General 2011, U.S. PUB.
HEALTH SERV. 1, 41 (2011).
9. Id. at 39.
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brings provider rights, so policymakers must determine the appropri-
ate role for pharmacists before tailoring the solution to that role. With
these goals in mind, this Part examines pharmacist provider status and
its close connection to reimbursement and analyzes the foreseeable
effects of federal pharmacist provider status on key aspects of our
health care system, including health care outcomes and cost savings.
A. What Is Provider Status?
“Provider” is a term that policymakers, health care professionals,
patients, legal scholars, health science scholars, private insurers, and
other stakeholders often use when referring to various health care
professionals. This term, however, has different meanings, so its usage
can sometimes be confusing. The dictionary,10 patients, and even some
legal scholars11 use the term provider generically to refer to health
care professionals providing patient care.
The law, however, defines a provider differently depending on the
context. For example, a health care professional might be a provider
for purposes of malpractice liability12 but not for purposes of reim-
bursement. In each of these examples, the law expressly enumerates
the type of health care professional, such as a physician or a pharma-
cist, who is legally a provider in a particular context. In doing so, the
law delineates who is and is not a provider; any accompanying bene-
fits or obligations of being a provider attach only to those satisfying
the provider definition.
10. Merriam Webster defines a “provider” as one who provides, such as a health
care provider. Provider, MERRIAM-WEBSTER, https://www.merriam-webster.com/dic-
tionary/provider?utm_campaign=sd&utm_medium=serp&utm_source=jsonld [https://
perma.cc/TV2U-8YJ8].
11. See William L. Allen & David B. Brushwood, Pharmaceutically Assisted Death
and the Pharmacist’s Right of Conscience, 5 J. PHARMACY & L. 1, 1 (1996) (“Pharma-
cists are health care providers who accept responsibility for the outcomes of drug
therapy by accurately processing medication orders, detecting and rectifying potential
problems with drug therapy, counseling patients concerning the anticipated effects of
drugs, and monitoring the results of drug use.”); David B. Brushwood, The Profes-
sional Capabilities and Legal Responsibilities of Pharmacists: Should “Can” Imply
“Ought”?, 44 DRAKE L. REV. 439, 441 (1996) (“Among health care providers, phar-
macists are uniquely qualified and situated to oversee the drug-use process.”). This
more generic use of “provider” is illustrated in many legal scholars’ works addressing
the issue of pharmacists’ refusal to dispense emergency contraception based on per-
sonal beliefs. See, e.g., Holly Teliska, Obstacles to Access: How Pharmacist Refusal
Clauses Undermine the Basic Health Care Needs of Rural and Low-Income Women,
20 BERKELEY J. GENDER L. & JUST. 229, 230 (2005) (discussing state bills permitting
pharmacist providers to deny women access to contraception because of a pharma-
cist’s beliefs); Maxine M. Harrington, The Ever-Expanding Health Care Conscience
Clause: The Quest for Immunity in the Struggle Between Professional Duties and
Moral Beliefs, 34 FLA. ST. U. L. REV. 779, 784–85 (2007) (referring to pharmacists as
providers in addressing a provider’s right to refuse care because of personal beliefs).
12. See, e.g., WASH. REV. CODE ANN. § 7.70.020(1) (West 2020) (defining health
care provider to include a pharmacist for purposes of health care malpractice claims).
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Generally, federal law is limited to defining who is or is not a pro-
vider for purposes of being eligible to apply for reimbursement from
federal payers such as Medicare13 (which provides health insurance
for disabled persons and persons sixty-five years of age or older).
At the federal level, achieving Medicare Part B14 reimbursement is
crucial for non-physician practitioners.15 This is partly because of the
large number of patients covered by Medicare. As of 2019, there were
almost 61 million Medicare beneficiaries, with 10,000 new enrollees
joining every day.16 By 2023, it is estimated that more than 80 million
Americans will qualify for Medicare.17 In addition to the large number
of Medicare patients, another reason Medicare reimbursement is
sought by health care professionals is that state and private insurers
tend to follow the federal government’s lead.18
Reimbursement, similar to other aspects of health care, is compli-
cated.19 Two of the primary Medicare reimbursement methods availa-
ble to non-physician providers are independently billing Medicare or
billing Medicare incident-to a physician. If the non-physician pro-
vider’s service is an integral part of the physician’s service, then the
non-physician provider’s service may be billed to Medicare under the
physician’s name as an incident-to service.20 In this form of billing,
because it is directly linked to the physician’s care, the claim is paid at
13. 42 U.S.C. § 1395–1395iii.
14. Medicare Part B covers outpatient services for elderly and disabled benefi-
ciaries; Medicare Part A covers hospital, or inpatient, services. See Craig B. Garner,
Medicare: The Perpetual Balance Between Performance and Preservation, 30 J. CON-
TEMP. HEALTH L. & POL’Y 279, 281–82 (2014) (providing a brief history of Medicare
and the coverage provided by parts A and B).
15. John S. Linehan, The Legal Implications of Pharmacist Provider Status and the
Transformation of an Industry, 18 AM. HEALTH L. ASS’N CONNECTIONS 20, 21 (2014).
Nurse practitioners are an example of a mid-level practitioner receiving “near-univer-
sal recognition under the state and private insurance programs after achieving pro-
vider status under Medicare Part B.” Id. (citing John Michael O’Brien, How Nurse
Practitioners Obtained Provider Status: Lessons for Pharmacists, 60 AM. J. HEALTH-
SYS. PHARMACISTS 2301, 2306 (2003)).
16. Seema Verma, The Future of Medicare Program Integrity, CTRS. FOR MEDI-
CARE & MEDICAID SERVS. (Oct. 21, 2019),  https://www.cms.gov/blog/future-medi-
care-program-integrity [https://perma.cc/ATS9-FJUR].
17. Erica M. Tolle et al., A Survey of Pharmacists’ Preparedness for Provider Sta-
tus Implementation, 57 J. AM. PHARMACISTS ASS’N S284, S284 (2017).
18. Barbara J. Safriet, Health Care Dollars and Regulatory Sense: The Role of Ad-
vanced Practice Nursing, 9 YALE J. ON REGUL. 417, 468 (1992). For instance, once
nurse practitioners achieved provider status under Medicare Part B, they also re-
ceived broader recognition from state and private insurance programs. Linehan, supra
note 15, at 21.
19. See Kevin Liptak, Trump: ‘Nobody Knew Health Care Could Be So Compli-
cated’, CNN: POL., https://www.cnn.com/2017/02/27/politics/trump-health-care-compli-
cated/index.html (Feb. 28, 2017, 4:10 AM) [https://perma.cc/2KAE-9ZLZ].
20. Alice G. Gosfield, The Ins and Outs of “Incident-To” Reimbursement, 8 FAM.
PRAC. MGMT. 23, 24 (2001) (thoroughly discussing the history and rules regarding
incident-to billing).
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100% of the physician fee schedule.21 Non-physician providers who
independently bill Medicare are typically reimbursed by Medicare at
85% of physician reimbursement rates.22 This lower reimbursement
rate accounts for the fact that a physician’s services were not neces-
sary, enabling the physician to care for a more clinically complex pa-
tient while reducing the health care system’s costs.23 Regardless of
how a non-physician ultimately bills Medicare, independently or inci-
dent-to, the service the provider is billing for must be within the pro-
vider’s scope of practice24 or permitted by state statute.
For a health care professional to be eligible to seek reimbursement
from Medicare Part B, the health care professional must be defined as
a provider in section 1861 of the Social Security Act.25 Currently, phy-
sicians, nurse practitioners, and physician assistants are included in the
list of providers, but pharmacists are not.26 Since pharmacists are not
providers27 under section 1861 of the Social Security Act,28 they are
unable to bill Medicare for their pharmacist services, unlike the recog-
nized providers.29 Nurse practitioners’ and physician assistants’ ability
to bill for services30 is one reason they outnumber pharmacists in out-
patient settings.31
Unlike in 1965 when Medicare was created,32 pharmacists in 2020
do more than lick, stick, count, and pour.33 Yet pharmacists are still
reimbursed according to the historical dispensing model, where phar-
macists were primarily drug sellers paid for the drugs plus a dispensing
21. Id. at 23.
22. Id. at 26.
23. Clay C. Johnson, A Case for an Efficient System: How Relaxing Midlevel Pro-
vider Supervision and Prescriptive Authority Laws Will Reduce Costs and Increase
Access to Health Care in Alabama, 45 CUMB. L. REV. 565, 593 (2015).
24. See Georgette Gustin, Allied Health Professionals Should Provide Only Those
Services That Are Within Their Scope of Practice, 9 J. HEALTH CARE COMPLIANCE 23,
63 (2007) (explaining the importance of allied health professionals, such as nurse
practitioners and physician assistants, billing for services within their scopes of
practice).
25. Social Security Act § 1861, 42 U.S.C. § 1395(k)(a)(2)(B), (x)(s).
26. Social Security Act § 1861, 42 U.S.C. § 1395(x)(s).
27. Johanna L. Keely, Pharmacist Scope of Practice, 136 ANNALS INTERNAL MED.
79, 83 (2002) (“[P]harmacists are not approved providers under Medicare except to
perform immunizations . . . .”).
28. 42 U.S.C. § 1395(x)(s).
29. Scott J. Knoer, Allison R. Eck & Amber J. Lucas, A Review of American
Pharmacy: Education, Training, Technology, and Practice, 2 J. PHARM. HEALTH
CARE & SCIS. 32, 37 (2016).
30. See Johnson, supra note 23, at 571–72 (providing an overview of insurance
reimbursement for mid-level providers).
31. Knoer, Eck & Lucas, supra note 29, at 36.
32. See Social Security Amendments of 1965, Pub. L. No. 89-97, § 102(a), 77 Stat.
275 (codified as amended at 42 U.S.C. § 1395).
33. See Green, supra note 1, at 1476.
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fee.34 Pharmacists’ reimbursement has not kept pace with their ex-
panding skills and contributions to the health care system.
To be clear, pharmacists currently provide some direct patient care,
although they are not often reimbursed for the actual level of service
provided to patients.35 For example, anticoagulation-ambulatory-care
clinics have been successful settings for pharmacists and are usually
welcomed by physicians36 since the pharmacists relieve the physicians’
burden of monitoring and adjusting anticoagulation medicines.37
Pharmacists in these clinics educate patients, order laboratory tests,
and adjust medications as needed.38 These pharmacists are not rogue,
acting entirely on their own. Rather, they collaborate closely with
physicians, establishing a collaborative practice agreement and regu-
larly communicating with the physicians and other prescribers.39 Al-
though the pharmacists’ patient care provided in an anticoagulation
clinic may decrease the number of patient visits to the emergency de-
partment and the frequency of patient admissions to the hospital,40
Medicare’s failure to reimburse pharmacist services means that such
clinics must find alternative funding mechanisms rather than simply
billing Medicare directly for the pharmacists’ care. Alternatively,
many accountable care organizations and other health care organiza-
tions may exclude pharmacists because pharmacists are unable to be
reimbursed for most Medicare services.41 While many hospitals allo-
cate other available funds to cover the pharmacist costs of operating
an anticoagulation clinic, these clinics are unsustainable in the long
term without pharmacist independent billing.42
34. Terri V. Newman et al., Optimizing the Role of Community Pharmacists in
Managing the Health of Populations: Barriers, Facilitators, and Policy Recommenda-
tions, 25 J. MANAGED CARE & SPECIALTY PHARMACY 995, 996 (2019).
35. See Keely, supra note 27, at 80–81 (discussing pharmacists’ role in drug ther-
apy programs, intensive care units, and local clinics).
36. Donna Young, Medicare Compensation Would Open Pharmacist-Managed
Service to More Patients, 59 AM. J. HEALTH-SYS. PHARMACY 811, 812 (2002).
37. Other examples of possible pharmacy-managed programs include asthma and
diabetes management. See, e.g., Terri V. Newman et al., Impact of Community Phar-
macist-Led Interventions in Chronic Disease Management on Clinical, Utilization, and
Economic Outcomes: An Umbrella Review, 16 RSCH. SOC. & ADMIN. PHARMACY
1155, 1156 (2020).
38. See Keely, supra note 27, at 80–81.
39. See id.
40. Young, supra note 36, at 811.
41. Lisa English Hinkle, Pharmacists: Aren’t You Really Providers Already? – Part
One, NAT’L L. REV. (Apr. 21, 2015), https://www.natlawreview.com/article/pharma-
cists-aren-t-you-really-providers-already-part-one [https://perma.cc/V8PN-HEKK].
42. Medicare compensation would open pharmacist-managed services to more pa-
tients. Young, supra note 36, at 811 (describing Shore Health Systems of Maryland
initiating and operating its anticoagulation clinic using funds from the hospital
foundation).
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Since state law governs the licensure of health care professionals,43
most of the legal definitions of a provider are found in state law and
thus differ from state to state. In some states, such as California44 and
Ohio,45 the legislature deems pharmacists as health care providers
with the authority to perform health care services. By including phar-
macists on the list of health care providers, state legislatures may give
pharmacists greater recognition, perhaps increasing their professional
stature and encouraging pharmacists’ further contributions to patient
health care. Legislative declarations of pharmacist provider status
alone, however, do not govern another critical component of provider
status: payment for services rendered. If pharmacists, as health care
providers, are to be reimbursed for services from payers, the legisla-
ture must mandate coverage46 or establish discretionary coverage.47
Eligibility for reimbursement is critical to incentivizing any health care
professional to provide patient care to the fullest extent possible.
For purposes of this Article, state pharmacist provider status refers
to the status that state legislatures establish for pharmacists, while fed-
eral pharmacist provider status refers to a status created by federal
law, either a statute or administrative rule, that enables pharmacists to
seek reimbursement from Medicare for health care services. Only fed-
eral law, not state law, can establish Medicare reimbursement for a
provider. Having federal pharmacist provider status may increase the
likelihood of reimbursement from Medicaid and private insurers, as
these payers often follow Medicare’s lead regarding the types of
health care professionals deemed to be providers for reimbursement
purposes.
B. The Likely Effects of Federal Pharmacist Provider Status on the
American Health Care System
Improving health care outcomes, strengthening interdisciplinary
health care teams, and contributing to health care cost savings are all
likely—and intertwined—impacts of federal pharmacist provider sta-
tus on the health care system.
43. See Gabriel Scheffler, Unlocking Access to Health Care: A Federalist Approach
to Reforming Occupational Licensing, 29 HEALTH MATRIX 293, 304–12 (2019) (pro-
viding a history of state health care professionals’ licensure and its impact on access to
health care).
44.  CAL. BUS. & PROF. CODE § 4050 (West 2020).
45.  OHIO REV. CODE ANN. § 1751.01(Y) (West 2019–2020).
46. See WASH. REV. CODE ANN. § 48.43.094 (West Supp. 2019) (requiring reim-
bursement by most private insurers for specific pharmacist performed health care
services).
47. See OR. REV. STAT. § 414.764 (2017) (permitting reimbursement for pharma-
cist services from the Oregon Health Authority).
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1. Improving Health Care Outcomes
When we think of patient health care outcomes, individual patients
and their good or bad health outcomes may come to mind first. While
these are important, particularly to the individual patient, the health
care system is also concerned with improving population health out-
comes. Federal legislation, including the Patient Protection and Af-
fordable Care Act (“PPACA”)48 and the Health Information
Technology for Economic and Clinical Health (“HITECH”) Act (pro-
moting adoption of electronic health records and transfer of individual
health information to public health agencies that can use data to as-
sess population health),49 has encouraged the development and use of
population-level outcome metrics.50 Pharmacists may provide services
promoting both components of health care outcomes: individual pa-
tient health care outcomes and population health care outcomes.
While a limited number of pharmacists may already contribute to
improving health care outcomes,51 federal pharmacist provider status
will enable more pharmacists to do so. For instance, one area where
pharmacists may improve health care outcomes is using their medica-
tion expertise in optimizing medication-related patient outcomes.52
Pharmacists may do this by reducing a patient’s potential adverse drug
events or by motivating patients to adhere to their medication ther-
apy. Additionally, several health sciences studies suggest that pharma-
cists can improve patient outcomes with respect to diseases and
conditions.53 Notably, researchers analyzing the impact of community
pharmacy interventions on chronic disease management found that
community pharmacists can improve clinical outcomes in chronic dis-
48. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119
(2010). See Barry R. Furrow, Regulating Patient Safety: The Patient Protection and
Affordable Care Act, 159 U. PA. L. REV. 1727, 1737 (2011) (providing an overview of
the PPACA’s strategy for improving patient health outcomes and population health).
49. Health Information Technology for Economic and Clinical Health Act, Pub. L.
No. 111-5, § 13407, 123 Stat. 226, 269–71 (2009).
50. Efthimios Parasidis, Health Outcomes Metrics and the Role of Financial Deriv-
ative Instruments in the Health Care Industry, 10 IND. HEALTH L. REV. 447, 450–59
(2013) (providing an overview of population health outcomes metrics).
51. See Jessica L. Van Beek, The Future for Pharmacists: Does Physician-Pharma-
cist Collaborative Practice Mean Collaborative Liability?, 36 J. LEGAL MED. 442,
444–46, 458 (2015) (analyzing pharmacist participation in patient care through the use
of collaborative practice agreements between pharmacists and physicians).
52. Paul Denvir & Jeffrey Brewer, “How Dare You Question What I Use to Treat
This Patient?”: Student Pharmacists’ Reflections on the Challenges of Communicating
Recommendations to Physicians in Interdisciplinary Health Care Settings, 30 HEALTH
COMMC’N 504, 505 (2015).
53. But see Margaret McConnell et al., Architecting Process of Care: A Random-
ized Controlled Study Evaluating the Impact of Providing Nonadherence Information
and Pharmacist Assistance to Physicians, 55 HEALTH SERVS. RSCH. 136, 136–37, 144
(2020) (analyzing results of a pilot study finding that pharmacists’ phone calls to pa-
tients to help physicians address medication adherence did not improve adherence
outcomes).
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eases including diabetes, HIV/AIDS, and cardiovascular and respira-
tory diseases.54 Chronic diseases are frequent drivers of morbidity and
mortality as well as high health care costs.55
2. Improving Interdisciplinary Health Care Teams
The purpose of interdisciplinary health care teams is to combine the
knowledge and skills of individual health care providers to provide an
improved patient care experience.56 Ever since the Institute of
Medicine’s report entitled Health Professions Education: A Bridge to
Quality,57 recommending that “[a]ll health professionals should be ed-
ucated to deliver patient-centered care as members of an interdiscipli-
nary team,”58 such teamwork has been increasingly emphasized by the
medical59 and other health care professions,60 including pharmacy.61
Some pharmacists have experience being part of an interdisciplinary
health care team pursuant to a collaborative practice agreement
(“CPA”),62 but lack of provider status and the associated eligibility for
54. Newman et al., supra note 37, at 1155, 1165 (noting that part of this study’s
significance is that for pharmacists to successfully transition from dispensing drugs to
providing clinical care, they will need to demonstrate the impact of their clinical inter-
ventions on patients’ outcomes).
55. Diabetes, heart disease, hypertension, asthma, and mental health are chronic
health conditions accounting for about 80% of America’s $3.5 trillion annual health
care expenditures. Nathaniel Meyersohn, This Is the CVS of the Future, CNN BUS.,
https://www.cnn.com/2019/02/16/business/cvs-health-healthhub-minuteclinic-aetna/in-
dex.html (Feb. 16, 2019, 7:21 AM) [https://perma.cc/S33D-P3FY].
56. Denvir & Brewer, supra note 52, at 505.
57.  COMM. ON THE HEALTH PROS. EDUC. SUMMIT, INST. OF MED. OF THE NAT’L
ACADS., HEALTH PROFESSIONS EDUCATION: A BRIDGE TO QUALITY 45–46 (Ann C.
Greiner & Elisa Knebel eds., 2003) (explaining that interdisciplinary teamwork is one
of five core health professional competencies (The others are providing patient-cen-
tered care, employing evidence-based practice, applying quality improvement, and us-
ing information technology.)).
58. Id. at 121.
59. Linda Morton, Howard Taras & Vivian Reznik, Teaching Interdisciplinary
Collaboration: Theory, Practice, and Assessment, 13 QUINNIPIAC HEALTH L.J. 175,
180–82 (2010) (providing the history of interdisciplinary collaboration within the med-
ical profession).
60. See Rosaly Correa-de-Araujo, Evidence-Based Practice in the United States:
Challenges, Progress, and Future Directions, 37 HEALTH CARE FOR WOMEN INT’L 2, 3
(2016) (addressing nurses’ involvement in health care teams and the implications for
patient outcomes).
61. See K. L. Carter et al., Improved Latent Tuberculosis Therapy Completion
Rates in Refugee Patients Through Use of a Clinical Pharmacist, 21 INT’L J. TUBERCU-
LOSIS & LUNG DISEASE 432, 432 (2017) (suggesting incorporating clinical pharmacists
into interdisciplinary health care teams enhances patients’ medication adherence and
improves public health outcomes).
62. See generally Nat’l All. State Pharmacy Ass’ns et al., Advancing Team-Based
Care Through Collaborative Practice Agreements: A Resource and Implementation
Guide for Adding Pharmacists to the Care Team, CTRS. FOR DISEASE CONTROL &
PREVENTION (2017), https://www.cdc.gov/dhdsp/pubs/docs/cpa-team-based-care.pdf
[https://perma.cc/RYZ3-2FFP] (thoroughly discussing the legal ramifications of CPAs
in all states). Under CPAs, physicians and other health care professionals, including
advanced practice nurses and physician assistants, may delegate some of their author-
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reimbursement prevent widespread inclusion of pharmacists as mem-
bers of interdisciplinary teams. Federal pharmacist provider status can
improve interdisciplinary teams because the addition of a pharmacist
to the team brings enhanced medication knowledge.
3. Contributing to Health Care Cost Savings
In January 2018, Amazon, Berkshire Hathaway, and JPMorgan
Chase & Co. founded an independent company focusing on providing
U.S. employees with quality, cost-effective health care.63 Media cover-
age of this announcement initially generated excitement in the health
care industry.64 While any impact of this new venture remains to be
seen,65 it does highlight how much the United States, including its
businesses, is eager for high-quality, low-cost health care.
A recent research study estimates that there were approximately
$528.4 billion in drug-related-morbidity-and-mortality costs in one
year in the United States.66 These costs include the direct medical
costs associated with requiring additional medications and needing to
access additional care by visiting a physician’s office, a hospital, or an
emergency department.67 Pharmacists, as medication experts, should
be able to assist in decreasing these costs by improving patient adher-
ity to pharmacists. See id. at 8 (noting that almost all states permit some level of
pharmacist-collaborative-practice authority, although not all states permit delegation
of a prescriber’s authority via a CPA); Linehan, supra note 15, at 24. For instance, in a
Texas clinical practice group, pharmacists collaborate with physicians and advanced
practice nurses to provide chronic care management of diseases such as asthma, dia-
betes, and hypertension. Wei C. Yuet et al., Pharmacist-Led Chronic Care Manage-
ment Services, 17 ANNALS FAM. MED. 465, 465 (2019) (highlighting that significant
time and resources were invested to build processes facilitating revenue-cycle man-
agement). At a North Carolina community teaching hospital, an interdisciplinary
team, including a pharmacist, community paramedics, cardiology nurse practitioners,
and physician assistants, works together to transition patients from the hospital to the
patients’ homes. Amanda Boykin et al., Interprofessional Care Collaboration for Pa-
tients with Heart Failure, 75 AM. J. HEALTH-SYS. PHARMACY e45, e46 (2018).
63. Nicolas P. Terry, “Prime Health” and the Regulation of Hybrid Healthcare, 8
N.Y.U. J. INTELL. PROP. & ENT. L. 42, 43–45 (2018) (providing a framework for bet-
ter understanding the roles of large technology companies in health care). Six months
later, the threesome announced that Dr. Atul Gawande would lead the company. Id.
at 58. One year later, the company announced its new name, Haven. John Tozzi, Ama-
zon-JPMorgan-Berkshire Health-Care Venture To Be Called Haven, BLOOMBERG
(Mar. 6, 2019, 3:05 PM), https://www.bloomberg.com/news/articles/2019-03-06/ama-
zon-jpmorgan-berkshire-health-care-venture-to-be-called-haven [https://perma.cc/
58EH-689G]. As this Article was going to press, Haven announced it will cease oper-
ating at the end of February 2021. Emily Flitter & Karen Weise, Bold Health Care
Venture Comes to a Quiet Ending, N.Y. TIMES, Jan. 5, 2021, at B1.
64. Tozzi, supra note 63.
65. Haven does have a website, containing limited information about its vision for
health care. Vision, HAVEN, https://havenhealthcare.com/vision [https://perma.cc/
6QMQ-A8SF].
66. Watanabe, McInnis & Hirsch, supra note 6, at 832.
67. Id. (noting that these are direct medical costs and do not include direct non-
medical costs such as transportation or caregiving costs).
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ence to medication therapies and helping avoid a patient’s need for
additional treatment.
As our health care system focuses on cost-effective care, there is a
growing expectation that health care providers and health care facili-
ties can demonstrate their contributions toward lowering health care
costs68 and improving population health outcomes.69 Demonstrating
this, however, is difficult for pharmacists because they lack provider
status.70 Without provider status, pharmacists cannot bill indepen-
dently for their services, and so existing administrative and medical
claims data, which typically capture the pharmacists’ contribution
under the prescribers’ claims,71 do not adequately reflect pharmacist-
provided patient services.72 Not only does the data not reflect pharma-
cists’ contributions to patient care, but more significantly, absent reim-
bursement, pharmacists lack incentives to provide patient care
services. In turn, this deprives the health care system and patients of
opportunities for improved patient care and lower health care costs.
Research studies indicate projected “cost savings of pharmacist-pro-
vided direct patient care services,”73 but additional data are necessary
to better understand pharmacists’ ability to reduce health care costs.
One growing area where pharmacists may benefit patients and reduce
health care costs is geriatric pharmacy. Older Americans often stock-
pile prescription medications, including those that are outdated, no
longer needed, or potentially cause harm,74 which pharmacists can
help evaluate and likely tailor to patient need.
Federal pharmacist provider status, with its ability for pharmacists
to independently bill Medicare, will facilitate pharmacists’ ability to
conclusively demonstrate what seems likely—that pharmacists can in-
deed help the U.S. health care system realize cost savings.
68. See Knoer, Eck & Lucas, supra note 29, at 32.
69. Newman et al., supra note 34, at 995.
70. For this reason, pharmacists consider validating their value beyond prescrip-
tion dispensing to be one of the largest challenges for the pharmacy profession. Jenna
Pizzi, Industry Analysis: Preparing for the Future of Healthcare and Pharmacy, US-
CIENCES (Apr. 16, 2019), https://www.usciences.edu/news/2019/industry-analysis-pre-
paring-for-the-future-of-healthcare-and-pharmacy.html [https://perma.cc/2VR8-
CXHJ].
71. See Elaine Nguyen & John T. Holmes, Commentary, Pharmacist-Provided
Services: Barriers to Demonstrating Value, 59 J. AM. PHARMACISTS ASS’N 117, 118
(2019) (demonstrating a cycle where pharmacists’ lack of ability to bill independently
for clinical services perpetuates barriers to demonstrating the value of pharmacists’
clinical services).
72. See id.
73. Patrick C. Harper, Commentary, Pharmacist Provider Status Legislation: Pro-
jections and Prospects, 55 J. AM. PHARMACISTS ASS’N 203, 206 (2015).
74. See Aaron E. Carroll, The Unsung Role of the Pharmacist in Patient Health,
N.Y. TIMES (Jan. 28, 2019), https://www.nytimes.com/2019/01/28/upshot/pharmacists-
drugs-health-unsung-role.html [https://perma.cc/WR5B-UD9R] (noting that “66 per-
cent [of older adults] take five drugs or more per day, and 27 percent take 10 or more
per day”).
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III. THE FEDERAL PHARMACIST PROVIDER STATUS TIPPING POINT
Malcolm Gladwell, in his bestselling book, The Tipping Point: How
Little Things Can Make a Big Difference,75 described how something
considered “outside the norm” can rapidly be normalized once a tip-
ping point is reached.76 Gladwell explores social epidemics such as
sweeping fashion trends,77 changing crime waves,78 and the rise of
teenage smoking79 by comparing them to viral epidemics.80 Both viral
and social epidemics are a function of transmission and the environ-
ment.81 Social epidemics tip when at least one “change agent”82 cata-
lyzes a social virus, causing it to move from equilibrium to an
epidemic.83 Essentially, Gladwell believed that social epidemics take
place when there is “the right messenger with the right message in the
right social context.”84 Using Gladwell’s framework, this Part asserts
that automation, mergers, transitions to value-based care, and ad-
vanced pharmacy technicians are “little things”85 that, combined, may
form the right context for change.86 Moreover, these changes to the
health care landscape may help modify the message from one of the
providers fighting over scope of practice and reimbursement to one of
improving patient care by better utilizing pharmacists in direct patient
care.
A. Robots and Automation in Pharmacies
Similar to technological changes impacting our day-to-day lives,
with ride shares such as Uber and Lyft changing how we move about
and Amazon Fresh and other online grocery delivery services chang-
ing how we shop for our food, technological advancements also
change components of our health care system. For instance, Uber per-
mits health care providers to book rides for patients, and these rides
75. MALCOLM GLADWELL, THE TIPPING POINT: HOW LITTLE THINGS CAN MAKE
A BIG DIFFERENCE (1st ed., 2000).
76. Id. at 7–9, 13–14.
77. See id. at 3–5.
78. See id. at 133–68.
79. See id. at 216–52.
80. See id. at 15–29.
81. Id. at 18.
82. Id. at 18–19.
83. See id.
84. Jackie Gardina, The Tipping Point: Legal Epidemics, Constitutional Doctrine,
and the Defense of Marriage Act, 34 VT. L. REV. 291, 292 (2009).
85. GLADWELL, supra note 75, at 150.
86. See id. at 172.
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are reimbursed by health insurers.87 Robots now assist in surgeries88
and also provide bedside care.89
Technological advances are also changing parts of pharmacy prac-
tice.90 Pharmacy dispensing, once associated with mortars and pestles
for compounding medication, is one area of pharmacy practice that is
becoming increasingly automated.91 For example, pharmacies utilize
barcodes (like the ones in grocery stores) to improve patient safety by
reducing human error.92 Barcodes enable pharmacists to more accu-
rately track inventory,93 prepare patient doses, and appropriately dis-
pense and administer prescriptions.94 Computers have been used
extensively in pharmacy practice since the mid-1990s to assist pharma-
cists screening for drug-drug interactions,95 providing patient drug in-
formation,96 evaluating patient dosage ranges,97 and screening for
patient drug allergies.98 More recently, computers and robots now
drive the automated filling and dispensing machinery used by some
hospitals and large pharmacies.99
Widespread automation in pharmacies may benefit our health care
system, patients, and pharmacists.100 Increasingly, pharmacists are
87. Carolyn Said, Lyft, Uber See Gold in Business Market, S.F. CHRON., Feb. 16,
2020, at 2.
88. Drew Simshaw et al., Regulating Healthcare Robots: Maximizing Opportunities
While Minimizing Risks, 22 RICH. J.L. & TECH. 1, 1 (2016).
89. Valarie K. Blake, Regulating Care Robots, 92 TEMP. L. REV. 551, 551 (2020).
90. See Marc R. Summerfield et al., Use of Pharmacy Delivery Robots in Intensive
Care Units, 68 AM. J. HEALTH-SYS. PHARMACY 77, 82 (2011) (evaluating a robotic
delivery system for medications at the University of Maryland Medical Center and
suggesting that “robots . . . have contributed to the pharmacy’s image of being techno-
logically savvy . . . .”); Knoer, Eck & Lucas, supra note 29, at 34.
91. Knoer, Eck & Lucas, supra note 29, at 34.
92. Id.
93. See Justin D. Evans, Improving the Transparency of the Pharmaceutical Supply
Chain Through the Adoption of Quick Response (QR) Code, Internet of Things (IoT),
and Blockchain Technology: One Result: Ending the Opioid Crisis, 19 PITT. J. TECH.
L. & POL’Y 35, 53 (2019) (proposing the use of quick response code, the internet of
things, and blockchain technology to build off of bar code technology and further
integrate prescription medication tracking to reduce the unwitting use of counterfeit
medications).
94. Knoer, Eck & Lucas, supra note 29, at 34.
95. Gary G. Cacciatore, Computers, OBRA 90 and the Pharmacist’s Duty to Warn,
5 J. PHARMACY & L. 103, 112 (1995) (exploring potential pharmacist liability arising
from negligent use of a computer or failure to use a computer while practicing
pharmacy).
96. See Husam Dauod et al., Robust Receding Horizon Control Strategy for Re-
plenishment Planning of Pharmacy Robotic Dispensing Systems, 59 ROBOTICS & COM-
PUT.-INTEGRATED MFG. 177, 177 (2019).
97. Elisabeth Belmont & Adele A. Waller, The Role of Information Technology in
Reducing Medical Errors, 36 J. HEALTH L. 615, 616 (2003).
98. Summerfield et al., supra note 90, at 77.
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voicing their concerns101 that complying with corporate policies and
performance metrics is leading to prescription errors that pose risks to
patient safety.102 These concerns are not new; news media have cov-
ered similar incidents for over a decade.103 The foreseeable benefits of
automated prescription filling include saving additional health care
costs associated with patients receiving and taking incorrect prescrip-
tion medications, improving patient care by avoiding potential adverse
health events to patients, and facilitating better workplace environ-
ments for pharmacists.
In addition to automation, robots are being used more in health
care,104 including in pharmacies. Pharmacies use robots primarily for
tasks related to preparation and delivery of prescription medica-
tions.105 For instance, robots used to prepare toxic chemotherapy
medications can improve pharmacists’ safety by decreasing exposure
to the toxic drugs from “spills, aerosol exposure, and needle sticks.”106
And robots used to prepare and deliver prescription medications to
intensive care units also decrease the time from prescription ordering
to ultimate drug delivery to the patient.107 Automation, robots, and
other technological advances may enable pharmacists to have more
time for direct patient care, but pharmacists are unlikely to accept this
new role and its associated responsibilities without federal pharmacist
provider status.
B. Pharmacy Mergers and Acquisitions
Through mergers, the various components of our health care sys-
tem, such as hospitals, insurers, and pharmacies, may achieve econo-
mies of scale and scope, which increases their ability to compete in the
101. See Ellen Gabler, At Walgreens, Complaints of Medication Errors Go Missing,
N.Y. TIMES, Feb. 21, 2020, at A1 (reporting pharmacists’ concerns that “unreasona-
ble” corporate expectations are leading to pharmacists making errors in filling pre-
scriptions and failing to comply with safety procedures) (internal quotations omitted).
102. Ellen Gabler, How Chaos at Chain Pharmacies Is Putting Patients at Risk,
N.Y. TIMES, Feb. 1, 2020, at A1 (reporting that corporate policies in some major drug
store chains may be causing pharmacists to make errors in filling and dispensing pre-
scription medications).
103. See Kimberly A. Burns & Alan R. Spies, A Pharmacist’s Duty to Warn: Pro-
moting the Acceptance of a Consistent Legal and Professional Standard, 47 DUQ. L.
REV. 1, 23–24 (2009) (discussing news reports of pharmacy chains potentially creating
an environment where errors are more likely to occur when pharmacists are en-
couraged to quickly fill a large number of prescriptions in order to meet corporate
expectations).
104. Simshaw et al., supra note 88, at 10–18 (providing an overview of types of
robots used in the health care environment).
105. Id.
106. Andrew C. Seger et al., Impact of Robotic Antineoplastic Preparation on
Safety, Workflow, and Costs, 8 J. ONCOLOGY PRAC. 344, 344 (2012).
107. Summerfield et al., supra note 90, at 80.
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changing health care landscape. While marketplace competition,108
improved quality of care,109 increased patient access,110 and health
care cost saving111 are often the focus of merger debates, the impact
on pharmacists and the practice of pharmacy is often overlooked.112
The CVS–Aetna merger of “healthcare giants,”113 the Cigna–Express
Scripts merger, and Amazon’s acquisition of PillPack will likely fur-
ther tip pharmacists closer to federal pharmacist provider status by
moving pharmacists closer to providing primary care.
Amazon’s almost $1 billion acquisition of PillPack, a customizable
prescription medication platform,114 may make ordering prescription
medications online an acceptable—and possibly preferable—alterna-
tive to brick-and-mortar pharmacies.115 Moreover, this acquisition will
likely motivate Amazon to improve supply chain efficiencies,116 fur-
ther increasing pharmacy automation and relieving pharmacists of
more mundane tasks.
The CVS–Aetna merger exemplifies the popular effort to change
the health care delivery system and increase access to health care ser-
vices.117 One likely outcome of the CVS–Aetna merger118 is the ex-
108. Jaime S. King & Erin C. Fuse Brown, The Anti-Competitive Potential of Cross-
Market Mergers in Health Care, 11 ST. LOUIS U. J. HEALTH L. & POL’Y 43, 44 (2017).
109. Kent Bernard, Taking Quality of Health Care Seriously in Provider Merger
Analysis, 11 ST. LOUIS U. J. HEALTH L. & POL’Y 161, 174 (2017).
110. Melissa Quintana, Measuring Hospital Post-Merger Effects: Developing a Stan-
dard for Antitrust Analysis, 21 N.Y.U. J. LEGIS. & PUB. POL’Y 957, 984 (2019).
111. Roger D. Blair, Christine Piette Durrance & D. Daniel Sokol, Hospital Merg-
ers and Economic Efficiency, 91 WASH. L. REV. 1, 62 (2016).
112. See generally John Gitta, Comment, The Impact of Merger & Acquisitions on
Smaller Pharmacy Market Participants and Consumers, 27 ANNALS HEALTH L. AD-
VANCE DIRECTIVE 163, 163 (2018) (providing alternative solutions to improve phar-
macy accessibility following the changing pharmacy landscape created by mergers and
acquisitions). Consolidation through mergers, however, may also raise questions of
pharmacy accessibility particularly in underserved communities. Id. at 174.
113. United States v. CVS Health Corp., 407 F. Supp. 3d 45, 48 (D.D.C. 2019)
(describing CVS and Aetna as “healthcare giants,” specifically CVS as “one of the
largest companies in the United States” and Aetna as the “nation’s third-largest
health-insurance company” (internal quotations omitted)).
114. Mollie Levy, Marketing Medicine to Millennials: Preparing Institutions and
Regulations for Direct-to-Consumer Healthcare, 55 CAL. W. L. REV. 521, 531 (2019).
PillPack delivers prescription medications, dietary supplements, and over-the-counter
medications in individualized daily packages, making patient adherence to medica-
tions more convenient. Id. at 540.
115. Jim Butschli, Amazon’s PillPack Acquisition Could Transform Online Phar-
macy Market, HEALTHCARE PACKAGING (July 16, 2018), https://www.healthcarepack
aging.com/home/article/13295041/amazons-pillpack-acquisition-could-transform-on-
line-pharmacy-market [https://perma.cc/E7G6-PR4J].
116. Gary Forger, Pharma Races Toward Its Future, MOD. MATERIALS HANDLING
(Dec. 10, 2019), https://www.mmh.com/article/pharma_races_towards_its_future
[https://perma.cc/Q7E2-VCEP].
117. Julia Kapchinskiy, The Duality of Provider and Payer in the Current Health-
care Landscape and Related Antitrust Implications, 55 SAN DIEGO L. REV. 617, 618
(2018) (discussing the blurred health care lines in the CVS–Aetna merger); Leslie A.
Saxon & Anjali Doshi, Editorial Commentary: Re-Inventing Chronic Disease Manage-
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pansion119 of CVS’s MinuteClinics, clinical facilities within CVS
stores.120 Patients visit MinuteClinics seeking treatment for health
concerns such as minor cuts, the flu, or strep throat. Patients may
choose to visit a MinuteClinic rather than a physician’s office because
the MinuteClinic is more readily accessible both geographically and
temporally, and it may cost them less money.121
More significantly, CVS’s merger with Aetna is also likely to ex-
pand the volume of primary care provided in MinuteClinics (poten-
tially doubling it)122 as well as expand the type of primary care by
increasing its management of chronic diseases.123 With more potential
primary care available, patients may gravitate toward MinuteClinics
ment as a Service—Medication Adherence Solutions Are Ground Zero, 29 TRENDS
CARDIOVASCULAR MED. 118, 118 (2019).
118. Because of the interrelatedness of pharmacies, insurers, and pharmacy benefit
managers, it is notable that in addition to operating its community pharmacy chain
and MinuteClinics, CVS also operates Caremark, a pharmacy benefit manager. Off.
Pub. Affs., Judge Decides CVS-Aetna Final Judgment Is in the Public Interest and
Grants United States’ Motion, DEP’T JUST. (Sept. 4, 2019), https://www.justice.gov/opa/
pr/judge-decides-cvs-aetna-final-judgment-public-interest-and-grants-united-states-
motion [https://perma.cc/FGC3-NRQB]. “Three PBMs (CVS Caremark, OptumRx,
and Express Scripts) control approximately 75% of the PBM market . . . .” Katherine
L. Gudiksen & Jaime S. King, The Burden of Federalism: Challenges to State Attempts
at Controlling Prescription Drug Costs, 39 J. LEGAL MED. 95, 105–06 (2019). PBMs,
which establish and negotiate drug coverage terms between pharmacies and insurers,
are basically invisible to the consumer or patient. Kate Cox, Cigna, Express Scripts
Receive Final Approval, Close $67 Billion Deal, CQ ROLL CALL, Dec. 21, 2018, at 1,
2018 WL 6719719.
119. Currently, there are approximately 1,100 MinuteClinics located in CVS and
Target stores in thirty-three states and the District of Columbia. Now Offering Access
to MinuteClinic at No Cost to the Member, AETNA (2019),  https://
www.townebenefits.com/media/103536/aetna-minuteclinic-flyer-final.pdf [https://
perma.cc/7FCL-G89S]. Approximately one-ninth of CVS locations currently contain
a MinuteClinic. Drew Gerber, CVS Plans Could Change the Face of Health Care,
NAT’L J. (Mar. 15, 2018, 8:00 PM), https://www.nationaljournal.com/s/665317/cvs-
plans-could-change-face-health-care [https://perma.cc/PJL3-PH86].  Some Target
stores also have MinuteClinics. Rebekah Williams, Aetna: Now Offering MinuteClinic,
MESSER FIN. GRP.: CARRIER UPDATES (June 14, 2019), https://
www.messerfinancial.com/insurance-industry-news/carrier-updates/1567-aenta-now-
offering-minuteclinic [https://perma.cc/YA7L-LMT3] (suggesting there is plenty of
room for expanding the sheer number of MinuteClinics).
120. Gerber, supra note 119.
121. MinuteClinics charge less than outpatient clinics, urgent care facilities, and
emergency departments. Leemore S. Dafny, Perspective, Does CVS–Aetna Spell the
End of Business as Usual?, 378 NEW ENG. J. MED. 593, 593–95 (2018).
122. Testifying at a Congressional subcommittee, CVS Executive Vice President
Thomas Moriarty explained CVS’s vision of potentially doubling the amount of pri-
mary care services provided at MinuteClinics. Gerber, supra note 119.
123. Id.
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because they are convenient.124 Moreover, patients insured by Aetna
may be incentivized to use MinuteClinics and other CVS services.125
Although now care at facilities such as MinuteClinics is usually pro-
vided by nurse practitioners or physician assistants,126 if pharmacists
have federal pharmacist provider status and are able to independently
bill Medicare, it is likely pharmacists will play a greater role in provid-
ing some primary care services.127
C. Transitioning to Value-Based Care
Spurred in part by PPACA128 and the 2015 Medicare Access and
CHIP Reauthorization Act (“MACRA”),129 fee-for-service payment
models are being replaced with value-based reimbursement models.130
124. But see id. (reporting that CVS indicates that its primary care aims focus on
those patients lacking access to primary care rather than potentially siphoning off
patients with established primary care).
125. For example, an Aetna flyer encourages members interested in tobacco cessa-
tion and other public health goals to use MinuteClinics to focus on their health goals
“right in [their] own neighborhood.” A Convenient Way to Focus on Your Health —
Right in Your Own Neighborhood, AETNA (2013), http://www.usmc-mccs.org/employ/
benefits/documents/aetnacvsminuteclinicflyer.pdf [https://perma.cc/Z8V6-J6U8]. CVS
Health is another merger benefit for Aetna. Through CVS Health, Aetna now offers
Medicare beneficiaries blood pressure monitoring at home and coverage of fall pre-
vention supplies. Aetna’s 2020 Medicare Plans Connect Members with More Personal-
ized Care and Benefits in Their Homes and Communities, CVS HEALTH (Oct. 24,
2019), https://cvshealth.com/newsroom/press-releases/aetnas-2020-medicare-plans-
connect-members-with-more-personalized-care [https://perma.cc/23S6-9K88]. CVS
Health Chief Executive, Larry Merlo, announced that CVS–Aetna aims to provide
coverage for 80% of Medicare-eligible patients. Bruce Jaspen, CVS’ Aetna Targets 4
in 5 Medicare Seniors for Advantage Plans, FORBES (Aug. 8, 2019, 8:00 AM), https://
www.forbes.com/sites/brucejapsen/2019/08/08/cvs-aetna-targets-4-in-5-medicare-se-
niors-for-advantage-plans/#8ce5f2614b72 [https://perma.cc/R7SB-NT5W]. This would
be an increase from 75% in 2019. Bruce Jaspen, CVS Profits Jump amid National
HealthHub Expansion, FORBES (Aug. 7, 2019, 8:53 AM), https://www.forbes.com/
sites/brucejapsen/2019/08/07/cvs-profits-jump-amid-national-healthhub-expansion/
#1567cf534a70 [https://perma.cc/CK9G-MB6B]. 2020 marks the first year Medicare
Advantage Plans will be offered following the merger, further underscoring the signif-
icance of the different pathways for accessing primary care services at CVS stores.
126. Gerber, supra note 119.
127. Only time will tell as to whether CVS-Aetna’s large network of brick-and-
mortar access points to a variety of health care services will provide sufficient protec-
tion from online competition from dominant entities such as Amazon. Meyersohn,
supra note 55.
128. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119
(2010). Although value-based payment programs began more than a decade before
the PPACA was enacted, the PPACA financially incentivizes providers to achieve
good patient outcomes at lower costs. Susan Adler Channick, The ACA, Provider
Mergers and Hospital Pricing: Experimenting with Smart, Lower-Cost Health Insur-
ance Options, 6 WM. & MARY POL’Y REV. 95, 96 (2015).
129. Medicare Access and CHIP Reauthorization Act, Pub. L. No. 114-10, 129 Stat.
87 (2015).
130. E.g., Rick Mayes & Soleil Shah, MACRA and Medicare’s Elusive Quest for
Fairness and Value with Physician Payment Policy: Speeding Up the Transition to “Big
Med”, 11 ST. LOUIS U. J. HEALTH L. & POL’Y 235, 236 (2018) (tracing the evolution
of Medicare physician payment from the beginning of Medicare through the enact-
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Historically, based on a fee-for-service model, Medicare and other
payers paid physicians for each service provided, such as a wellness
visit, an x-ray, or a surgery.131 Under this model, physicians acting as
“rational and selfish economic actors . . . are incentivized to deliver
high-volume, high-cost care.”132 The fee-for-service payment system
led the United States to have the most expensive health care system in
the world, sometimes with lower quality than other nations.133 Gradu-
ally, fee-for-service systems are transitioning to value-based systems.
Value-based care strives to better align provider reimbursement
with payer and patient incentives.134 Thus, rather than being paid
based on the number of procedures and services that a provider per-
forms, payment is based on the quality of care provided and cost sav-
ings.135 Including pharmacists as eligible Medicare providers in a
value-based care system will allow pharmacists’ expertise to directly
contribute to quality of care and cost savings by providing patient ser-
vices and enhancing interdisciplinary teamwork across the patient
continuum of care.136
The weight that value-based care adds to the tipping point may de-
pend, in part, on the 2021 presidential administration. For example,
although the Trump Administration claimed to support the movement
to value-based care, it also emphasized the need to reduce the regula-
tory burden associated with value-based care, shifting from mandatory
to voluntary programs and decreasing any federal oversight,137 likely
slowing down our transition to value-based care. Transition speed im-
pacts the weight value-based care adds to the tipping point scale; the
slower the transition, the less weight. Biden’s Administration is likely
to increase the speed of our national progress toward value-based
care, thereby pushing us closer to the tipping point.
ment of MACRA); Richard J. Zall, Jeff J. Marwil & Mara A. Wilber, MACRA: Qual-
ity-Based Payment and Its Implications for Stakeholders, 35 AM. BANKR. INST. J. 16,
16 (2016) (explaining the two payment pathways under MACRA: the merit-based
incentive payment system (“MIPS”) and the alternative payment model (“APM”)).
131. Wendy Netter Epstein, Revisiting Incentive-Based Contracts, 17 YALE J.
HEALTH POL’Y L. & ETHICS 1, 6–7 (2017).
132. Id.
133. Id.
134. Amy B. Monahan, Value-Based Mandated Health Benefits, 80 U. COLO. L.
REV. 127, 128–29 (2009).
135. Anne B. Claiborne, Julia R. Hesse & Daniel T. Roble, Legal Impediments to
Implementing Value-Based Purchasing in Healthcare, 35 AM. J.L. & MED. 442, 443
(2009).
136. Newman et al., supra note 34, at 996.
137. Elizabeth Tobin-Tyler, Health Justice in the Age of Alternative Facts and Tax
Cuts: Value-Based Care, Medicaid Reform, and the Social Determinants of Health, 12
ST. LOUIS U. J. HEALTH L. & POL’Y 29, 49 (2018).
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D. Advanced Pharmacy Technicians
Also driving the need for federal reform are the developing changes
to how pharmacy technicians are utilized in pharmacies. As with many
of the other changes in the health care system, using pharmacy techni-
cians may enable pharmacists to have a greater role in direct patient
care.
Pharmacy technicians are critical pharmacy personnel who perform
non-judgmental tasks under the supervision of a licensed pharma-
cist.138 The precise responsibilities of a pharmacy technician are gov-
erned by the state laws where the pharmacy technician is working.139
Typically, pharmacy technicians prepare and compound medication
while advanced pharmacy technicians may take on additional tasks
such as obtaining patients’ medication histories and working with
other advanced pharmacy technicians to dispense medications.140
Pharmacies utilize pharmacy technicians to complete limited tasks
at a lower cost, which permits pharmacists to focus more on patient
care. Delegating more of the prescription-dispensing tasks to phar-
macy technicians is one method of increasing time for pharmacists to
provide direct patient care services.141 Typically, a pharmacist verifies
a prescription’s accuracy prior to dispensing it to a patient. This verifi-
cation may also be completed using a tech-check-tech program, in
which a qualified pharmacy technician checks the work of another
qualified pharmacy technician prior to the drug being dispensed.142
While tech-check-tech programs began in hospital and long-term care
pharmacies, their use is expanding into community pharmacies.143 An
Iowa study indicates that a tech-check-tech program in a community
pharmacy144 increases the time available for pharmacists to provide
direct patient care.145 In an eight-hour work shift, the study reports
that the total number of patient services provided by pharmacists in-
creased from twenty-three to approximately forty-one,146 almost
doubling the number of patient services. Notably, this study found a
138. See Steven W. Huang, The Omnibus Reconciliation Act of 1990: Redefining
Pharmacists’ Legal Responsibilities, 25 AM. J.L. & MED. 417, 420 (1998).
139. Knoer, Eck & Lucas, supra note 29.
140. Id.
141. Michael Andreski et al., The Iowa New Practice Model: Advancing Technician
Roles to Increase Pharmacists’ Time to Provide Patient Care Services, 58 J. AM. PHAR-
MACISTS ASS’N 268, 269 (2018).
142. Id. (explaining that pharmacy technicians must be certified in order to partici-
pate in a tech-check-tech program).
143. Id. (describing the results of an eighteen-month pilot project in Iowa commu-
nity pharmacies in which qualified pharmacy technicians verified a refilled prescrip-
tion by another qualified pharmacy technician).
144. Id. at 273 (describing the community pharmacies in this study as small chain or
independent pharmacies; similar research results may not occur at higher-volume or
large chain pharmacies).
145. Id. at 272.
146. Id.
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significant increase in non-reimbursed pharmacist services.147 Having
more time may enable pharmacists to provide increased direct patient
care services, but without commensurate reimbursement, providing
additional patient services remains unsustainable.
Pharmacy technicians are now preparing to assume more advanced
roles in the pharmacy, including managing robotics and assuming
more supervisory roles. As these advanced roles evolve, pharmacists
may have more time and energy to function at the top of their licen-
sure—if the law permits them. Combined, automation, mergers,
value-based care, and the use of pharmacy technicians, among other
changes in the health care system, create the motivation and context
for more comprehensive federal action that state efforts cannot
provide.
IV. LEARNING FROM STATE AND FEDERAL EFFORTS TO
ESTABLISH PHARMACIST PROVIDER STATUS
These many changes in our health care landscape148 are likely to
force the issue of federal pharmacist provider status. State statutes es-
tablishing pharmacist provider status are common, but they are not a
satisfactory substitute for federal provider status, especially given
these external pressures. State statutes and legislative histories, how-
ever, illustrate some of the important parameters, such as who can
provide what service where, that any federal solution will need to ad-
dress. Focusing on the West Coast states, this Part analyzes the key
elements of state statutory pharmacist provider status that can inform
federal law. This Part also examines pharmacist provider status efforts
at the federal level because the failure of these efforts, to date, signi-
fies how important the changes in the health care system are in creat-
ing a tipping point making federal pharmacist provider status not just
possible but probable.
A. State Pharmacist Provider Status Legislation: A Spotlight on the
West Coast States’ Provider Status Legislation
California, Oregon, and Washington were among the first states to
statutorily establish pharmacist provider status.149 As provider status
migrated up the coast from California, each state chose different regu-
latory mechanisms to address the issue of pharmacist provider status.
147. Id.
148. See supra Part III.
149. Arizona and West Virginia also enacted pharmacist provider status laws dur-
ing the same time frame as California, Oregon, and Washington. 2019 State Legislative
Wins for Community Pharmacists, NAT’L CMTY. PHARMACISTS ASS’N 1, 4–5 (Jan. 17,
2020), http://www.ncpa.co/pdf/2019-state-legislative-wins-com-pharm.pdf [https://
perma.cc/6RN2-CEKD]. Other states continue to enact and implement pharmacist
provider status statutes. For example, Ohio enacted Substitute S.B. 265 in 2019. S.B.
265, 132d Gen. Assemb., Reg. Sess. (Ohio 2018).
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In recognizing pharmacists as health care providers, some states
have chosen to simultaneously establish new categories of pharmacists
with advanced training or clinical practice. California statutorily rec-
ognizes all pharmacists as health care providers, including a new phar-
macist category, the Advanced Practice Pharmacist.150 In a similar
fashion, Oregon adds a new category of clinical pharmacy practition-
ers151 to the types of pharmacists recognized as health care provid-
ers.152 Washington, however, creates no new category of advanced or
clinical pharmacists; all Washington pharmacists are considered prov-
iders under the state’s “every category of provider” classification.153
While a pharmacist may perform any health care service within her
scope of practice, the question remains whether the pharmacist is eli-
gible for reimbursement for such service. State statutes typically spec-
ify the precise reimbursable services a pharmacist may perform. These
services, however, are a subset of a pharmacist’s entire scope of
practice.
For instance, a California pharmacist’s scope of practice includes
administering prescribed drug and biological products; providing pa-
tient consultations; educating patients regarding drug therapy, disease
management, and disease prevention; ordering and interpreting labo-
ratory tests to monitor and manage drug therapies (including con-
trolled substances); furnishing nicotine replacement products;
administering vaccines; and providing travel medications and hormo-
nal contraception.154 A California Advanced Practice Pharmacist may
perform additional services, including assessing patients, referring pa-
tients to other providers, and initiating, adjusting, and discontinuing
drug therapy.155 The only Medicaid-reimbursable156 services a Califor-
nia pharmacist may provide, however, are furnishing nicotine replace-
ment products, administering vaccines, and providing travel
medications and hormonal contraception. With none of the Advanced
Practice Pharmacist services eligible for reimbursement,157 California
150. CAL. BUS. & PROF. CODE § 4016.5 (West 2020).
151. Clinical pharmacy practitioners in Oregon engage in a team approach to pro-
viding patient care, including post-diagnostic disease state management. OR. REV.
STAT. ANN. § 689.005(30) (West, Westlaw through ch. 19 of 2020 2d Spec. Sess.).
152. OR. REV. STAT. ANN. § 689.005 (Westlaw, current through ch. 19 of 2020 First
Spec. Sess.).
153. Other states, such as Ohio, have also opted not to create special categories of
pharmacists. See OHIO REV. CODE ANN. § 1751.01 (West 2019).
154. CAL. BUS. & PROF. CODE § 4052 (West 2020).
155. CAL. BUS. & PROF. CODE § 4052.6 (West 2020).
156. CAL. WELF. & INST. CODE § 14132.968 (West 2020). In order to achieve any
reimbursement, two bills had to be enacted in California: California Senate Bill 493
(declaring the practice of pharmacy to be a profession), S.B. 493, 2013–2014 Reg.
Sess. (Cal. 2013), and California Assembly Bill  1114 (mandating reimbursement at
85% for certain services), Assemb. B. 1114, 2015–2016 Reg. Sess. (Cal. 2016).
157. If California Senate Bill 1285, introduced in 2018, had passed instead of dying
in the Senate, it would have required health care service plans to cover Advanced
Practice Pharmacist services. S.B. 1285, 2017–2018 Reg. Sess. (Cal. 2018).
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reimburses pharmacist providers for only a small subset of services
within all California pharmacists’ scope of practice.
Similar to California’s reimbursement scheme, Washington’s reim-
bursement for pharmacist providers applies only to certain pharmacist
services.158 Washington distinguishes between major medical benefits
and drug benefits.159 Pharmacist provider status requires reimburse-
ment for services complying with state-mandated health benefits and
within a pharmacist’s scope of practice.160 These services, covered by a
patient’s major medical benefit, could also be provided by a physician,
physician assistant, or advanced registered nurse practitioner.161 Drug
benefits are not covered by Washington’s statute. Unlike California
and Washington’s reimbursement scheme, Oregon’s permits any
health care service within a pharmacist’s scope of practice to be eligi-
ble for reimbursement.162 Oregon’s statutory scheme, however, per-
mits, rather than requires, public and private insurers to reimburse a
pharmacist.163
Perhaps most notably, the West Coast states refrained from placing
any limitations on where a pharmacist could perform a service as a
provider.164 In these states, a pharmacist’s provider status is not linked
to practicing in a specific community, such as an underserved
community.165
While states granting pharmacists provider status permit pharma-
cists to bill private insurers166 or Medicaid programs,167 states lack the
jurisdiction to enable pharmacists to bill Medicare.
158. Most Washington State private health plans are required to compensate phar-
macists; public plans are not required to reimburse pharmacists. See Thomas K.
Hazlet, Tanya E. Karwaki & Donald F. Downing, Commentary, Pathway to Pharma-
cist Medical Provider Status in Washington State, 57 J. AM. PHARMACISTS ASS’N 116,
118 (2017).
159. Id.
160. Washington State mandates additional benefits beyond those required by the
PPACA. WASH. REV. CODE § 48.43.094 (2020).
161. Washington’s statute does not impact patients’ drug benefits, which are dis-
tinct from major medical benefits. Hazlet, Karwaki & Downing, supra note 158, at
116.
162. OR. REV. STAT. § 414.764 (2020).
163. Id.
164. See, e.g., Assemb. B. 1114, 2015–2016 Reg. Sess. (Cal. 2016); S.B. 493,
2013–2014 Reg. Sess. (Cal. 2013).
165. Compare Assemb. B. 1114, 2015–2016 Reg. Sess. (Cal. 2016), and S.B. 493,
2013–2014 Reg. Sess. (Cal. 2013), with Pharmacy and Medically Underserved Areas
Enhancement Act, H.R. 592, 115th Cong. (1st Sess. 2017) (proposing federal legisla-
tion allowing pharmacist service provider status but limiting where the services can be
provided).
166. E.g., WASH. REV. CODE § 48.43.094 (2020).
167. E.g., CAL. WELF. & INS. CODE § 14132.968 (West 2020).
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B. Federal Pharmacist Provider Status
Federal policy stakeholders, including administrative agencies and
nonprofit organizations, support expanded pharmacist contributions
to the U.S. health care system. In 2012, the Centers for Disease Con-
trol and Prevention (“CDC”) reported that engaging pharmacists in
the health care system would improve quality and lower costs.168 A
few years earlier, the U.S. Surgeon General praised a U.S. Public
Health Service report recommending pharmacists be recognized as
health care providers.169 Administrative agencies were not the only
entities interested in propelling pharmacists to practice closer to the
top of their licensure; at least one influential nonprofit organization
providing leadership on health care issues also advocated for in-
creased access to pharmacists. According to the Institute of
Medicine’s (“IOM”) 2000 landmark report, To Err Is Human: Build-
ing a Safer Health Care System, hospital pharmacists are an essential
resource and should always be available.170
As this Subpart illustrates, however, the CDC’s and U.S. Surgeon
General’s support, among others, have failed to lead to the enactment
of legislation establishing federal pharmacist provider status. Briefly
analyzing the trends of previous unsuccessful federal bills addressing
federal pharmacist provider status is useful in better understanding
the context of federal pharmacist provider status in our changing
health care landscape. Specifically, this history of repeated bill failure,
even with progressively narrower bills, demonstrates the significance
of Gladwell’s Tipping Point, for arguably without reaching this Tip-
ping Point, there is little evidence that federal pharmacist provider sta-
tus will be established any time soon.
1. Legislating Federal Pharmacist Provider Status
More than eight bills addressing Medicare Part B’s coverage of
pharmacist services have been introduced in Congress. Although the
original bill began with a broad concept of pharmacist provider status,
168. Cynthia M. Morrison et al., A Program Guide for Public Health: Partnering
with Pharmacists in the Prevention and Control of Chronic Diseases, NAT’L CTR. FOR
CHRONIC DISEASE PREVENTION & HEALTH PROMOTION 1, 6 (Aug. 2012), https://
www.cdc.gov/grand-rounds/pp/2014/20141021-pdf-pharmacist-role-508.pdf [https://
perma.cc/Z55R-MCJL].
169. See Linehan, supra note 15, at 21. The Office of the Surgeon General is part of
the Department of Health and Human Services. Off. of the Surgeon Gene., About the
Office of the Surgeon General, U.S. DEP’T HEALTH & HUM. SERVS. (May 14, 2019),
https://www.hhs.gov/surgeongeneral/about/index.html [https://perma.cc/YBR2-
4AVD].
170. COMM. ON QUALITY OF HEALTH CARE IN AM., INST. OF MED. OF THE NAT’L
ACADS., TO ERR IS HUMAN: BUILDING A SAFER HEALTH CARE SYSTEM 194 (Linda
T. Kohn, Janet M. Corrigan & Molla S. Donaldson eds., 2000). IOM has been
renamed and is now called the Health and Medicine Division. About the Health and
Medicine Division, NAT’L ACADS., https://www.nationalacademies.org/hmd/about
[https://perma.cc/9N42-QEPS].
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subsequent bills narrowed the breadth of pharmacist provider status.
Regardless of the approach each bill took regarding pharmacist pro-
vider status, these bills all died quickly after being referred to
subcommittees.
The first and broadest of these bills, the “Medicare Pharmacist Ser-
vices Coverage Act of 2001,”171 likely represents pharmacists’ ulti-
mate goal, which has been continually modified in subsequent bills.
This bill would have facilitated reimbursement for pharmacist services
provided to a Medicare beneficiary anywhere in the United States,
subject to state law scope-of-practice restrictions.172 Over the follow-
ing few years, limitations were added to subsequent bills in an effort
to identify components of a bill capable of gaining traction in Con-
gress. The restrictions targeted the type of patient treated, such as
high-risk asthmatic or diabetic patients,173 and the clinical skills of the
pharmacists.174 Yet, even with these limitations, the bills were unable
to become law.
The most recent iterations of this federal bill tried a different strat-
egy, allowing a greater number of pharmacists to participate in provid-
ing reimbursable pharmacist services, but limiting where these
services can be provided.175 Under the more recent proposed bills, any
pharmacist, licensed and acting within her scope of practice, could be
reimbursed and was not required to obtain additional advanced train-
ing or any other designation.176 The services, however, must be pro-
vided in a geographical location with a designated provider shortage
or vulnerable population.177 The types of locations where pharmacists
would have federal provider status are health professional shortage
areas, with provider shortages in primary care, dental or mental health
care,178 medically underserved areas or medically underserved popu-
171. Medicare Pharmacist Services Coverage Act of 2001, S. 974, 107th Cong. (1st
Sess. 2001).
172. Id. at § 2(b).
173. Medicare Medication Therapy Management Services Coverage Act of 2002,
H.R. 5539, 107th Cong. (2d Sess. 2002) (stating reimbursement would only be availa-
ble to a “qualified pharmacist” providing services in an “eligible State”).
174. Medicare Clinical Pharmacist Practitioner Services Coverage Act of 2004,
H.R. 4724, 108th Cong. (2d Sess. 2004) (requiring reimbursing only “clinical pharma-
cist practitioner[s]” providing services pursuant to a collaborative practice agreement,
or State certified, with prescriptive authority, and applied scientific principles to direct
patient care).
175. Pharmacy and Medically Underserved Areas Enhancement Act, H.R. 592,
115th Cong. (1st Sess. 2017); H.R. 4190, 113th Cong. (2d Sess. 2014).
176. The services must be otherwise covered if provided by a physician or incident
to a physician’s service. H.R. 4190 § 1(a)(3)(GG)(i); H.R. 592 § 2(a)(3)(HH)(i).
177. H.R. 592 § 2(a)(3)(HH)(iii); H.R. 4190 § 1(a)(3)(GG)(iii).
178. Health Res. & Servs. Admin., Health Professional Shortage Areas (HPSAs),
BUREAU HEALTH WORKFORCE, https://bhw.hrsa.gov/shortage-designation/hpsas
(May 2020) [https://perma.cc/FM73-6ABX].
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lations, with too few primary care providers, high infant mortality, or
a high elderly population.179
2. Federal Administrative Agency Rulemaking
In addition to the possibility of legislatively creating federal phar-
macist provider status, the same thing could be accomplished through
federal administrative agency rulemaking. Seema Verma, the Admin-
istrator of the Centers for Medicare and Medicaid (“CMS”), recently
suggested that the Trump Administration may consider granting phar-
macists federal provider status through administrative rulemaking.180
Verma’s comments build off of President Trump’s Executive Order on
Protecting and Improving Medicare for Our Nation’s Seniors.181 Ac-
cording to this executive order:
[T]he Secretary shall propose reforms to the Medicare program to
enable providers to spend more time with patients by:
(a) proposing a regulation that would eliminate burdensome regula-
tory billing requirements, conditions of participation, supervision
requirements, benefit definitions, and all other licensure require-
ments of the Medicare program that are more stringent than appli-
cable Federal or State laws require and that limit professionals from
practicing at the top of their profession;
(b) proposing a regulation that would ensure appropriate reim-
bursement by Medicare for time spent with patients by both pri-
mary and specialist health providers practicing in all types of health
professions; and
(c) conducting a comprehensive review of regulatory policies that
create disparities in reimbursement between physicians and non-
physician practitioners and proposing a regulation that would, to
the extent allowed by law, ensure that items and services provided
by clinicians, including physicians, physician assistants, and nurse
practitioners, are appropriately reimbursed in accordance with the
work performed rather than the clinician’s occupation.182
A regulation proposed under this executive order could establish
federal pharmacist provider status by permitting pharmacists to prac-
tice at the top of their licensure or to the fullest extent of their educa-
tion and training as the law permits. It could also remove the
Medicare billing barrier for pharmacists and ensure appropriate reim-
179. H.R. 4190 § 1(a)(3)(GG)(iii); H.R. 592 § 2(a)(3)(HH)(iii).
180. Michelle M. Stein, Verma Hints Pharmacists May Be Considered Providers
Under Medicare EO, INSIDE HEALTH POL’Y (Oct. 30, 2019, 12:44 PM), https://in-
sidehealthpolicy.com/daily-news/verma-hints-pharmacists-may-be-considered-provid-
ers-under-medicare-eo [https://perma.cc/KH89-QJ5B].
181. Protecting and Improving Medicare for Our Nation’s Seniors, 84 Fed. Reg.
53573, 53573 (Oct. 8, 2019).
182. Id. at 53574.
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bursement by Medicare, likely at 85% of the physician fee schedule,
for the time pharmacists spend providing patient services. It is possi-
ble, however, that the Trump Administration’s focus remained on
other policy issues, such as reducing drug costs, as opposed to pharma-
cist provider status, particularly in an election year. It is also possible
that internal conflict in the Administration was undermining any pol-
icy agenda.183
V. PREPARING FOR A FEDERAL SOLUTION TO PHARMACIST
PROVIDER STATUS
Given the transformations occurring in the health care system, it is
foreseeable that pharmacists will achieve federal provider status. The
real question is when and how. It could occur slowly after the state
laboratories have had time to complete their experiments with state
pharmacist provider status. If more states follow California’s example
of taking a two-step, multi-year approach to pharmacist provider sta-
tus with reimbursement, this timeline will stretch out even longer.184
More likely, as this Article asserts, federal pharmacist provider status
will happen sooner, driven in large part by our health care system’s
changes such as increased automation and health care mergers.185
To date, federal pharmacist provider status has not been achieved
because it is typically framed by stakeholders, particularly providers,
as a scope-of-practice and payment issue. This type of framing places
federal pharmacist provider status squarely in the turf war category,
likely contributing to policymakers’ reluctance to take up this issue.
More significantly, it ignores the larger health care system changes.
Federal pharmacist provider status may happen either through fed-
eral legislation or by federal agency administrative rulemaking.186 A
statutory fix would be preferable since it is less subject to the pendu-
lum swings of different administrations; while a federal rule would
achieve the same goal, it might not be as stable. Regardless of whether
the solution occurs by statute or rule, this Part analyzes the three key
issues that should be addressed by any federal solution: which phar-
macists can perform what health care services, what boundaries may
183. Yasmeen Abutaleb et al., Trump Health Promises Thwarted by Feuding Aides,
Shifting Orders, WASH. POST (Dec. 11, 2019), https://www.washingtonpost.com/
health/trump-health-promises-thwarted-by-feuding-aides-shifting-orders/2019/12/11/
7bf4f3e4-1c3b-11ea-87f7-f2e91143c60d_story.html, [https://perma.cc/3UBU-NJZD].
184. Three years after enacting S.B. 493, the California Legislature passed Assemb.
B. 1114 mandating reimbursement for pharmacists providing limited health care ser-
vices at 85% of the Medi-Cal physician fee schedule for certain services, including
furnishing self-administered hormonal contraception, nicotine replacement products,
travel medicines, naloxone, and vaccines. Liesl D. Reyes et al., Community Pharma-
cists’ Motivation and Barriers to Providing and Billing Patient Care Services, 8 PHAR-
MACY 145, 146 (2020).
185. See supra Part III.
186. See supra Part IV.
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be placed on pharmacists providing direct patient care, and how to
clarify pharmacists’ reimbursement. Finally, this Part examines the
barriers to a federal solution and proposes a way forward.
A. Who Can Perform What Services Where?
Identifying which health care professional can provide what services
where while eligible for reimbursement is the crux of provider status.
In establishing federal pharmacist provider status, federal policymak-
ers will need to determine which pharmacists can perform what ser-
vices where in the United States. Careful consideration of the states’
experiences187 answering the same questions at the state level, in addi-
tion to drawing from previously introduced federal bills, is helpful in
resolving these challenging questions at the federal level.
While some states, including California and Oregon, create new
pharmacist categories such as Advanced Practice Pharmacists188 or
clinical pharmacy practitioners189 as part of establishing state pharma-
cist provider status, other states, including Washington and Ohio, do
not create any special categories of pharmacists. Creating new phar-
macist categories has not proven particularly useful for pharmacists in
seeking reimbursement. In California, none of the Advanced Practice
Pharmacist services are eligible for reimbursement,190 leaving little in-
centive for pharmacists to undertake the required training.191 At the
federal level, policymakers should make provider status open to all
pharmacists without additional restrictions while creating a system to
verify a pharmacist’s ability to provide certain health care services.192
Even with education and advanced training, it is likely that Medicare,
as a federal payer, as well as any private or state payers that follow
Medicare’s reimbursement example, will require verification of phar-
macists’ capabilities prior to permitting them to independently bill for
their services. This verification may be accomplished using pharmacist
credentialing and privileging, a similar method for determining the
ability and competency of other health care providers.193 In fact, in
187. Id.
188. CAL. BUS. & PROF. CODE § 4016.5 (West, Westlaw through Ch. 372 of 2020
Reg. Sess.).
189. OR. REV. STAT. ANN. § 689.005 (West, Westlaw through 2020 Reg. Sess. of
80th Legis. Assemb.).
190. If California S.B. 1285, introduced in 2018, had passed, it would have required
health care service plans to cover Advanced Practice Pharmacist services. S.B. 1285
died in the Senate. S.B. 1285, 2017–2018 Reg. Sess. (Cal. 2018).
191. As of 2017, there were 130 Advanced Practice Pharmacists in California.
FAQs, CAL. PHARMACISTS ASS’N,  http://appharmacist.com/faqs/ [https://perma.cc/
TK5A-2TN9].
192. Lynette Bradley-Baker, Which Comes First—Credentialing and Privileging in
Pharmacy or Pharmacist Provider Status?, 78 AM. J. PHARM. EDUC. 1, 1 (2014).
193. Id.
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some states with pharmacist provider status, credentialing and
privileging are part of the legislation’s implementation process.194
Previous federal bills already indicate a feasible approach to what
services a pharmacist may perform as a provider for Medicare pur-
poses. Under the federal bills introduced in 2014 and 2017, a pharma-
cist must be licensed and acting within her scope of practice.195
Additionally, the services must be otherwise covered if provided by a
physician or incident to a physician’s service.196 This approach, while
perhaps appearing simplistic at first glance, is appropriate because it
covers the most significant boundaries on a pharmacist’s services. Li-
censure and scope of practice place necessary restrictions on the phar-
macist while leaving the covered services as broad as possible by
linking the services a physician may provide.
Federal bills restricting pharmacist federal provider status to areas
with the greatest need for health care services, including health pro-
fessional shortage areas or medically underserved areas, inherently
categorize pharmacists as physician extenders, helping alleviate a phy-
sician workforce shortage. This is certainly one viable role for phar-
macists in our health care system. While it restricts the number of
pharmacists eligible to participate based on geography, further legisla-
tion could expand federal provider status to the entire United States,
similar to how the nursing profession achieved its federal provider sta-
tus.197 But, as this Article argues, federal pharmacist provider status
will not be primarily driven by workforce shortages. Thus, the better
solution is to follow the states’ lead and not limit where a pharmacist
can perform services as a provider.
B. Placing Boundaries on Pharmacists’ Direct Patient Care
The potential expansion of primary care through facilities such as
MinuteClinics positions pharmacists to take on some functions of a
primary care provider, like pharmacists in other countries.198 Moreo-
ver, as automation in prescription dispensing increases199 and ad-
vanced pharmacy technicians are permitted to take on additional
responsibilities, further relieving pharmacists of many of the more
technical tasks involved in pharmacy practice, pharmacists will have
194. See S.B. 5557, 64th Leg., Reg. Sess. (Wash. 2015); Hazlet, Karwaki & Down-
ing, supra note 158, at 118.
195. H.R. 4190, 113th Cong. § 1(a)(3)(GG)(i) (2014); H.R. 592, 115th Cong.
§ 2(a)(3)(HH)(i) (2017).
196. H.R. 4190 § 1(a)(3)(GG)(ii); H.R. 592 § 2(a)(3)(HH)(ii).
197. Nurses were originally granted provider status in rural areas. See Linehan,
supra note 15, at 23.
198. Gerber, supra note 119.
199. See Jean Spinks et al., Commentary, Disruptive Innovation in Community
Pharmacy – Impact of Automation on the Pharmacist Workforce, 13 RSCH. SOC. &
ADMIN. PHARMACY 394, 395 (2017) (evaluating automated dispensing systems and
their impact on the pharmacist workforce).
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more time to devote to providing direct patient care.200 Dispensing
prescription medications has been a large component of pharmacy
practice, but it does not represent the expanded skill set of contempo-
rary pharmacists. Pharmacists earn a Doctor of Pharmacy degree201
often followed by advanced training through residencies,202 fellow-
ships,203 and board certifications.204 Pharmacists’ education and train-
ing have prompted recognition of pharmacists’ medication expertise
as “exceed[ing] any other health care provider’s.”205 Some of the
clinical services pharmacists may perform include managing chronic
diseases, preventing disease, coordinating transitions from inpatient to
outpatient care, and monitoring diseases.206 From a health policy per-
spective, it behooves us to encourage pharmacists to provide direct
patient care where their medication skills and clinical capabilities may
improve patient care outcomes but leaves unanswered the more chal-
lenging question of how to regulate pharmacists’ provision of direct
patient care.
Policymakers could institute a connection between medication ther-
apy and related direct patient care. Drug therapy is a significant part
of our approach to health care with almost 75% of all outpatient phy-
sician visits including some form of drug therapy.207 Along with the
increased use of pharmaceuticals comes an increased risk of poten-
tially avoidable patient harms caused by medication therapies.208 An
estimated 275,689 people in the United States die each year because
of drug-therapy-related problems.209 According to the American
Pharmacists Association, more than 1.5 million preventable medica-
200. See Carmen Guadalupe Rodriguez-Gonzalez et al., Robotic Dispensing Im-
proves Patient Safety, Inventory Management, and Staff Satisfaction in an Outpatient
Hospital Pharmacy, 25 J. EVALUATION CLINICAL PRAC. 28, 28 (2019) (describing how
robotic dispensing systems permit pharmacists to spend more time with patients).
201. Yang-Yi Lin, Evolution of Pharm D Education and Patient Service in the USA,
4 J. EXPERIMENTAL & CLINICAL MED. (SPECIAL ISSUE) 227, 228 (2012). The Doctor
of Pharmacy (PharmD) has been the entry-level degree since 2000. Knoer, Eck &
Lucas, supra note 29, at 33.
202. Knoer, Eck & Lucas, supra note 29, at 33 (explaining Post-Graduate Year One
residencies designed to enhance medication therapy skills and Post-Graduate Year
Two residencies designed to focus on a specific pharmacy practice area such as oncol-
ogy or pediatrics).
203. Id. at 34 (noting that there are fewer fellowship opportunities than residency
programs and that fellowships are designed to prepare the fellow for independent
research).
204. Id. (commenting that board certification is often required, or at least pre-
ferred, in advanced pharmacy practice settings).
205. Jon C. Schommer et al., Pharmacist Contributions to the U.S. Health Care Sys-
tem, 1 INNOVATIONS PHARMACY 1, 2 (2010).
206. Newman et al., supra note 37, at 1156, 1160–62.
207. Watanabe, McInnis & Hirsch, supra note 6, at 829.
208. Id.
209. Id. at 832.
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tion-related adverse events occur annually.210 If pharmacists partici-
pate more directly in patient care, this number will likely decrease.
While individually consulting with patients, pharmacists are often able
to “identify drug therapy problems, recommend cost saving alterna-
tives, and alert the medical team to patient barriers to care.”211 Ide-
ally, technological innovations and other changes should facilitate
improved patient-pharmacist relationships and better patient medica-
tion therapy outcomes.212
C. Resolving Reimbursement
The only way to achieve uniform eligibility for reimbursement from
the most important federal payer, Medicare, is to establish federal
pharmacist provider status. CVS’s lobbying of Capitol Hill for federal
pharmacist provider status213 illustrates the importance of indepen-
dent pharmacist billing of Medicare. Once Medicare sets the reim-
bursement standard for pharmacists, other payers, including state
payers and private insurers, will likely follow Medicare’s lead.214 Al-
though federal policymakers must address pharmacists’ reimburse-
ment, they should not necessarily follow the path of least resistance
and establish pharmacists’ provider reimbursement at 85% of the phy-
sician fee schedule, similar to nurse practitioners and physician assist-
ants. Further research may help determine if mimicking other
providers’ reimbursement schedules fully accounts for any difference
in provider training, education, and clinical capabilities.
Pharmacists may facilitate the provision of value-based and cost-
effective health care services by improving medication adherence and
measuring patient outcomes. Pharmacists may also help physicians
achieve their quality measures in a value-based care system.215 While
pharmacists may now be reimbursed for aiding physicians with meet-
ing their quality targets by billing incident-to a physician,216 billing
under a collaborative practice agreement,217 or via a separate contract
directly linking reimbursement to meeting the quality measures,218
210. Advancing the Value of MTM, AM. PHARMACISTS ASS’N, https://por-
tal.pharmacist.com/advancing-value-mtm [https://perma.cc/D753-SBXN].
211. Nathan Hemberg et al., Commentary, Innovative Community Pharmacy Prac-
tice Models in North Carolina, 78 N.C. MED. J. 198, 198 (2017) (explaining the evolv-
ing role of a community pharmacist at the Carolina Apothecary).
212. Muhammad Umair Khan et al., Could an Automated Machine Replace the
Pharmacist?, 13 RSCH. SOC. & ADMIN. PHARMACY 399, 399 (2017).
213. Gerber, supra note 119.
214. Linehan, supra note 15, at 20.
215. Raechel Moore et al., Letters, Enhancing Pharmacy Services in a Primary Care
Setting to Help Providers Improve Quality Performance Measures, 76 AM. J. HEALTH-
SYS. PHARMACY 1460, 1460 (2019) (explaining that pharmacists may impact approxi-
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none of these billing alternatives are as simple and effective as permit-
ting pharmacists to bill directly as a provider.
D. Existing Barriers to a Federal Solution
Although many payers may decide to follow Medicare regarding
any change to pharmacists’ eligibility to seek reimbursement, state
legislation may still be necessary to align pharmacist services with
state payer reimbursement. Federal action is needed first, however, to
establish a uniform policy across the nation for the most significant
federal payer, Medicare. Once that is accomplished, it is likely that
states will quickly follow suit and pharmacists will qualify for reim-
bursement commensurate with the services they provide to patients.
Scope of practice conflicts highlight the business aspect of the
health care system.219 Providers generally want to expand their own
scope of practice while limiting other providers’ scope of practice be-
cause scope of practice is closely linked to provider payment. A health
care provider’s scope of practice refers to the statutorily defined activ-
ities or areas in which a particular provider is authorized to prac-
tice.220 Physicians have the broadest scope of practice, while other
providers have more narrow scopes of practice.221 Because many dif-
ferent providers’ scopes of practice are not unique and may overlap
with other providers’ scopes of practices creating a conflict, scope of
practice has been referred to as “a regulatory train wreck in the
making.”222
The American health care system, long deferring to physician ex-
pertise as evidenced by our laws and health care practice norms,223
may benefit from encouraging non-physician health care practitioners
to practice at the top of their licensure.224 Yet, tensions among differ-
219. Health care, once considered an art, is now practiced as a business. Daniel R.
Santola, The Changing World of Medicine and the Law that Protects Its Patients, AS-
PATORE, May 2012, at *8, 2012 WL 1189457.
220. Barbara J. Safriet, Closing the Gap Between Can and May in Health-Care
Providers’ Scopes of Practice: A Primer for Policymakers, 19 YALE J. ON REGUL. 301,
303–04 (2002) (summarizing the conflicting stakeholder perspectives that legislators
will confront whenever addressing a scope of practice issue and noting that legislators
may not be well prepared to determine the boundaries of different types of
providers).
221. Id. at 316 (asserting that “[f]or historical, rather than logical, reasons, physi-
cians enjoy an overly expansive scope of practice, while all other [providers] are
overly restricted[ ]”).
222. Id. at 310–11.
223. William M. Sage, Assembled Products: The Key to More Effective Competition
and Antitrust Oversight in Health Care, 101 CORNELL L. REV. 609, 623 (2016) (ex-
plaining how American health care has been directed by physicians in a medicalist
model for more than a century).
224. See Matthew Murawski et al., Advanced-Practice Pharmacists: Practice Char-
acteristics and Reimbursement of Pharmacists Certified for Collaborative Clinical Prac-
tice in New Mexico and North Carolina, 68 AM. J. HEALTH-SYS. PHARMACY 2341,
2342 (2011) (indicating that pharmacists with advanced-practice designations have
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ent provider groups typically increase whenever one type of provider,
such as pharmacists, strives to gain something the other providers al-
ready have, such as federal provider status.225
It is foreseeable that powerful stakeholders such as physician and
nursing organizations may, at first, be against federal pharmacist pro-
vider status because of the threat to their reimbursement pathways.
For instance, it is forecast that between 2016 and 2030 the number of
advanced practice nurses will grow 6.8% each year, far exceeding the
increases forecast for physicians, 1.1%, and physician assistants,
4.3%.226 If this forecast proves accurate, the health system will have
many more advanced practice nurses, at least some of whom may
strive to prevent pharmacists from further entering into primary care.
Yet as the states’ success in achieving pharmacist provider status dem-
onstrates, pharmacy collaboration across professional boundaries may
win the support—or at least neutrality—of such stakeholders, permit-
ting controversial provider status bills to become law.227
In California, the California Medical Association (“CMA”) was
crucial to passing California’s pharmacist provider status bill, SB
493.228 With supporters asserting the bill would permit Californians to
access high quality care from pharmacists, reduce the costs and strain
on California’s health care system, and expand team-based care from
hospitals to community settings,229 opponents argued that the bill put
patients at risk.230 One opponent, the California Academy of Eye
Physicians and Surgeons, alleged that the bill suggested a “two-tiered
system where those who are less well-off make do with less trained
providers while those with greater resources (i.e. money) go wherever
they want.”231 After demanding amendments to the bill and requiring
closer collaboration with primary care providers or diagnosing
prescribers, CMA adopted a neutral position toward the bill. Once
CMA took a neutral stance, organized opposition to the bill ended,
and the bill was enacted.232
more prescriptive privileges than pharmacists without advanced-practice
designations).
225. Keely, supra note 27, at 84.
226. David I. Auerbach, Peter I. Buerhaus & Douglas O. Staiger, Implications of
the Rapid Growth of the Nurse Practitioner Workforce in the US, 39 HEALTH AFFS.
273, 273 (2020).
227. See B. Joseph Guglielmo & Sean D. Sullivan, Pharmacists as Health Care
Providers: Lessons from California and Washington, 1 J. AM. COLL. CLINICAL PHAR-
MACY 39, 40 (2018).
228. Id.
229. See Pharmacy Practice: Hearing on S.B. 493 Before the S. Bus. & Profs.
Comm., 2013–2014 Leg., Reg. Sess. (Cal. 2013) (statement of Dr. Ryan Gates, Senior
Clinical Pharmacist at Kern Medical Center, that this bill would permit physicians to
delegate “tedious tasks” to pharmacists).
230. California Bill Analysis, S.B. 493, 2013–2014 Reg. Sess. (Cal. 2013).
231. Id.
232. CMA never changed its opposition to the optometrist and nurse practitioner
bills. Guglielmo & Sullivan, supra note 227, at 40. The California Hospital Association
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Oregon’s pharmacist provider status bill also encountered resis-
tance from the Oregon Medical Association and Nurses Associa-
tion,233 as well as the Pharmaceutical Research and Manufacturers of
America (“PhRMA”).234 Oregon’s major health care providers, Leg-
acy Health and Kaiser Permanente Northwest, supported the bill,
viewing pharmacists as essential health care team members facilitating
access to quality health care.235 While this support was helpful in the
bill’s passage, some of the bill’s opposition may have dissipated after
realizing that permissive reimbursement is a limited threat, as insurers
are unlikely to voluntarily reimburse.236
Washington’s experience also highlights the significance of collabo-
rating across professional boundaries. Washington avoided strong op-
position from other providers such as physicians partly because
pharmacy advocates worked with the Washington State Medical Asso-
ciation (“WSMA”) to ensure that WSMA remained neutral towards
the bill.237
While pharmacists may want increased autonomy and an expanded
scope of practice,238 it is important to understand that the primary
question of whether pharmacists should be granted federal provider
status does not depend on pharmacists achieving either of these goals.
Health care associations, such as the American Medical Association,
that may be opposed to increasing pharmacists’ scope of practice to
include prescriptive authority239 may be neutral on pharmacist pro-
supported all three of these bills. Key State Issues, CAL. HOSP. ASS’N 1, 6 (Aug. 29,
2013) http://www.calhospital.org/sites/main/files/file-attachments/cha_key_state_is-
sues__8-29-13.pdf [https://perma.cc/BCB4-BC4Q].
233. Loren Bonner, Oregon Enacts Pharmacist Provider Status Law, 21 PHARMA-
CYTODAY 70, 70 (2015).
234. Pharm. Rsch. & Mfrs. Am., Statement of Opposition for Or. H.B. 2028, S. 362-
72960, Reg. Sess. (2015) (opposing the bill because pharmacists are not trained to
provide direct patient care).
235. Legacy Health, Legacy Health Support H.B. 2028, S. 362-65708, Reg. Sess.
(Or. 2015); Kaiser Found. Health Plan Nw., Support for H.B. 2028, Reg. Sess. (Or.
2015).
236. See Loren Bonner, Pharmacist Provider Status Now Law in Oregon, APHA
(June 18, 2015), https://www.pharmacist.com/article/pharmacist-provider-status-now-
law-oregon [https://perma.cc/84V2-RHA3].
237. Loren Bonner, Washington State Law: Pharmacists Now Providers in Private
Health Plans, APHA (May 12, 2015), https://www.pharmacist.com/article/washington-
state-law-pharmacists-now-providers-private-health-plans-0 [https://perma.cc/Y6L5-
JTXZ].
238. Linehan, supra note 15, at 20 (describing provider status as the “linchpin” of a
larger pharmacist movement to increase pharmacists’ role in our health care delivery
system). See also Leighanne Root, Closing the Primary Gap: Is Pharmacist Prescrip-
tive Authority the Answer?, 23 ANNALS HEALTH L. 66, 73 (2013) (advocating for state
legislatures to grant pharmacist prescriptive authority); Alex J. Adams & Krystalyn
K. Weaver, The Continuum of Pharmacist Prescriptive Authority, 50 ANNALS
PHARMACOTHERAPY 778, 778 (2016) (creating a framework for characterizing ex-
isting state models of pharmacist prescriptive authority).
239. Letter from the Am. Medical Ass’n opposing Idaho H.B. 182 to the Hon. Brad
Little, Governor of Idaho (Mar. 21, 2019) https://searchlf.ama-assn.org/undefined/
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vider status only altering reimbursement eligibility for pharmacists,
not changing pharmacists’ scope of practice.
Engaging in “turf wars,”240 or insisting that each provider type “stay
in [its] own lane,”241 may be a valid stance from a provider’s perspec-
tive, but how policymakers regulate various providers remains a
health policy issue. The question is not simply, “Will pharmacists stay
within their existing practice boundaries?” but, “Should our health
care system encourage pharmacists to help fill a health care gap?”242
This gap filling could include checking on your health status while at
your community pharmacy,243 or via a pharmacy app,244 or by using
telepharmacy.245 Such pharmacist actions need not replace your visits
to your physician or other prescriber but complement those visits. In-
fighting among provider groups is so entrenched in providers’ re-
sponses and behaviors that it may be necessary for legislators and
regulators to temper the conflicts.246
The professional responsibilities of physicians, nurse practitioners,
physician assistants, pharmacists, and potentially other health care
professionals will continue to overlap. Health care providers con-
ducting overlapping services may benefit patients and allow providers
to act as “[her] brother’s keeper.”247 Working collaboratively, each
health care provider can focus on delivering high-quality patient care




240. See Christopher Ogolla, Litigating Hypocrisy: Turf Wars Between Health Care
Professionals Regarding Diagnosis, Evaluation, and Treatment, 50 U. TOL. L. REV. 67,
69–70 (2018) (providing a thorough explanation of turf wars).
241. Comment made to Author by nurse attorney; Symposium Feb. 7, 2020.
242. See Root, supra note 238, at 71 (detailing how pharmacists may help close the
primary care gap by increasing patient adherence to medication therapies and de-
creasing unnecessary primary care visits to physicians for minor ailments).
243. See Lydia Ramsey Pflanzer, A Health Insurance Startup in North Carolina Is
Betting on Pharmacists in an Entirely New Approach to a $327 Billion Market, BUS.
INSIDER (May 1, 2019, 12:00 PM), https://www.businessinsider.com/troy-medicare-ad-
vantage-will-pay-pharmacists-to-keep-elderly-members-healthy-2019-4?IR=t [https://
perma.cc/G23Y-WSS2].
244. See Meghan Ross, Gadget Guide: Spark Health App Empowers Pharmacists,
PHARMACY TIMES (Nov. 17, 2015, 2:17 AM), https://www.pharmacytimes.com/publica
tions/career/2015/PharmacyCareers_November2015/gadget-guide-spark-health-app-
empowers-pharmacists [https://perma.cc/56GD-6JVD].
245. Almeta E. Cooper & Sidney S. Welch, All That Is Mobile: Impact on Your
Health Law Practice, 2015 AM. HEALTH L. ASS’N SEMINAR PAPERS 1, 5–6 (2015).
246. Safriet, supra note 220, at 323 (highlighting how legislator and regulator in-
volvement in resolving conflict between different provider groups is necessary if the
goal of protecting the public “is to be anything more than a gossamer-thin disguise for
professional self-interest embedded in law”).
247. Riff v. Morgan Pharmacy, 508 A.2d 1247, 1253 (Pa. Super. Ct. 1986) (describ-
ing the limited duty physicians, pharmacists, anesthesiologists, nurses, and support
staff have regarding acts and omissions).
248. See Keely, supra note 27, at 84.
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instance, physicians can maintain medical expertise and focus on pa-
tient diagnosis and treatment, while pharmacists can spend time with
patients, educating, counseling, and motivating them to adhere to
their medication therapy. Therefore, pharmacists can help physicians
focus on other, non-drug therapy patient health issues during their pa-
tient visits.249
The mere fact that other providers will be impacted is not a reason
to deprive pharmacists of federal provider status. Rather, the impacts
highlight the need for policymakers and stakeholders to consider, and
potentially address, scope of practice issues in any legislative or
rulemaking solution.
VI. CONCLUSION
We have not yet reached the tipping point for federal pharmacist
provider status, but we are certainly close. By definition, a tipping
point causes a quick and dramatic change250; in this case, the change
would be establishing pharmacists as eligible for Medicare reimburse-
ment. Legislators and regulators should proactively prepare for this
tipping point to reach Congress and CMS. Careful consideration of
any boundaries on pharmacists’ services, particularly regarding any di-
rect patient care, reimbursement levels, and other health care provid-
ers’ concerns, may yield a federal solution capable of reaping the
benefits of federal pharmacist provider status without accentuating
any risks.
249. See Maria Castellucci, Is There a Pharmacist in the House? Outpatient Settings
Need More Pharmacists but Lack of Reimbursement Makes That a Tough Sell, 49
MOD. HEALTHCARE 36, 37 (2019) (noting that pharmacist visits with patients may last
an hour while physician visits are often limited to twenty minutes per patient).
250. Specifically, Gladwell posits that each “Tipping Point” is marked by three
characteristics: contagiousness, many little causes contributing to a large effect, and
change occurring quickly not gradually. GLADWELL, supra note 75, at 9.
